Baqsimi is under clinical development by Amphastar Pharmaceuticals and currently in Phase III for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase III drugs for Type 1 Diabetes (Juvenile Diabetes) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Baqsimi’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Baqsimi overview

Glucagon (Baqsimi) is an anti hypoglycemic agent. It is formulated as dry powder for inhalational route of administration (DPI). Baqsimi is indicated for the treatment of severe hypoglycemia in patients with diabetes ages 4 years and above.

Glucagon (LY-900018, AMG-5041) is under development for the treatment of severe hypoglycemia in type 1 and type 2 diabetes patients. The drug candidate is administered through intranasal route. It acts by targeting the glucagon receptor. The drug candidate is a new biological entity (NBE). It was also under development for the treatment of common cold.

Amphastar Pharmaceuticals overview

Amphastar Pharmaceuticals (Amphastar), is a specialty pharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, intranasal and inhalation products. It sells insulin-active pharmaceutical ingredient products. The company’s key products include enoxaparin sodium injection; cosyntropin for injection; naloxone hydrochloride (HCl) injection and phytonadione injection; lidocaine jelly; amphadase hyaluronidase injection; epinephrine, naloxone, phytonadione, primatene mist and glucagon. Amphastar offers its products to alternate care sites, hospitals, clinics and doctors’ offices and long-term care facilities. The company markets its products through subsidiaries, specialty distributors, wholesalers and retailers in the US, the UK, France and China. Amphastar is headquartered in Rancho Cucamonga, California, the US.

For a complete picture of Baqsimi’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.